[#DIV28SUPER] NIDA Neuroscience update Dec 4, 2019

 

I.             Register for 2020 Genetics and Epigenetics Cross-Cutting Research Team (GECCRT) Meeting, January 13-14, 2020. NIDA HQ, 6001 Executive Blvd., Rockville, MD 20850.

II.           Neurobiology of the Opioid Epidemic, Biological Psychiatry, Volume 87(1), January 1, 2020 Eds. Edited by Rita J. Valentino, Walter Koroshetz, Nora D. Volkow

III.         Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) RFA-DA-20-026

 

-------

 

I.                     Register for 2020 Genetics and Epigenetics Cross-Cutting Research Team (GECCRT) Meeting, January 13-14, 2020. NIDA HQ, 6001 Executive Blvd., Rockville, MD 20850.

The purpose of this meeting to communicate new discoveries about the genetics and epigenetics of substance use disorders and facilitate new collaborations.

 

Agenda

 

Registration

Please download the registration form (PDF, 147KB) and return to NGCmeeting@nida.nih.gov. Registration, which is free, closes at Midnight on January  3, 2020. Registration is necessary to streamline security screening. People who have not pre-registered should plan on long lines through security. All participants must bring a state or federal ID (e.g. drivers license or passport). 

 

 

II.                   Neurobiology of the Opioid Epidemic, Biological Psychiatry, Volume 87(1), January 1, 2020 Eds. Edited by Rita J. Valentino, Walter Koroshetz, Nora D. Volkow

 

III.  Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) RFA-DA-20-026

Application deadline: January 15, 2020

 

Description:

The scientific objective of this FOA is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes. 

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309